Kjeldsen, S.E., Julius, S., Mancia, G., McInnes, G.T., Hua, T., Weber, M.A., Coca, A., Ekman, S., Girerd, X., Jamerson, K., Larochelle, P., Macdonald, T.M., Schmieder, R.E., Schork, M.A., Stolt, P., Viskoper, R., Widimsky, J. and Zanchetti, A. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. Journal of Hypertension, 24, 1405-1412. doi:10.1097/01.hjh.0000234122.55895.5b

has been cited by the following article:

• TITLE: Comparative study between the effect of Momordica charantia (wild and hybrid variety) on hypoglycemic and hypolipidemic activity of alloxan induced type 2 diabetic long-evans rats

  AUTHORS: Subbroto Kumar Saha, Md. Ezazul Haque, Dipa Islam, Md. Matiar Rahman, Md. Rezuanul Islam, Anzana Parvin, Shahedur Rahman

  KEYWORDS: Type 2 Diabetes Mellitus; Momordica Charantia; Alloxan, Hypoglycemic Effect; Hypolipidemic Effect; Glibenclamide

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.2 No.1, February 22, 2012

  ABSTRACT: This study was undertaken to evaluate the hypoglycemic and hypolipidemic effect of Momordica charantia (wild and hybrid variety) powder on alloxan induced type 2 diabetic male Long-Evans rats. Oral feeding of the M. charantia powder slightly decreased serum total cholesterol, triglyceride levels and LDL-cholesterol compared with wild, hybrid and standard drug. M. charantia wild variety showed more significant (p M. charantia did not show any significant effect on HDL-cholesterol and liver glycogen. Thus, results of the study prove that the wild variety of M. charantia fruit have potent antidiabetic and antilipidemic property.